Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer (EMERGE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03989362
Recruitment Status : Active, not recruiting
First Posted : June 18, 2019
Last Update Posted : November 24, 2021
Information provided by (Responsible Party):
Jounce Therapeutics, Inc.

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : April 30, 2022
Estimated Study Completion Date : July 31, 2022